22
Participants
Start Date
November 30, 2012
Primary Completion Date
June 30, 2016
Study Completion Date
September 30, 2016
PVX-410
Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
Winship Cancer Institute, Emory University, Atlanta
Illinois Cancer Specialists, Niles
University of Texas, MD Anderson Cancer Center, Houston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Lead Sponsor
OncoPep, Inc.
INDUSTRY